Xenetic Biosciences (XBIO) Peer Comparison

$2.34

$0.02 (0.65%)

As on 01-Oct-2026 09:34EDT

Market cap

$6 Mln

Revenue (TTM)

$3 Mln

P/E Ratio

--

P/B Ratio

1

Div. Yield

0 %

Edit

	Xenetic Biosciences (XBIO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	6	17,274	14,841	14,411	12,927
Revenue ($ Mln)	3	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	-2.48	491.50	755.85	860.62	413.60
Net Margin (%)	-75.90	17.67	71.69	35.33	24.86
RoE (%)	-36.75	110.09	--	42.98	430.03
Price to Earnings	--	36.40	17.63	18.29	33.40
Price-To-Book	0.96	39.70	8.91	7.82	88.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Xenetic Biosciences (XBIO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	3.26	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	0.00	1,982.07	103.47	85.67	363.07
Gross Profit	2.98	760.62	588.53	2,236.43	1,091.18
Operating Expenses	5.90	216.81	841.45	1,378.74	356.18
Operating Profit (EBIT)	-2.64	583.40	109.45	971.51	944.49
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-2.48	598.92	101.11	1,035.47	583.34
Provision for Tax	0.00	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	-2.48	491.50	755.85	860.62	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Xenetic Biosciences (XBIO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	6.07	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	0.00	187.89	384.48	288.55	2,089.43
Current Liabilities	0.89	1,435.43	464.70	361.93	344.44
Total Liabilities	8.36	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Xenetic Biosciences (XBIO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	0.31	1,006.90	895.24	1,243.41	1,644.38
Current Assets	6.65	1,050.29	1,389.84	1,250.82	933.02
Total Assets	8.36	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	0.00	120.10	449.89	165.93	2,146.65
Net Current Assets	5.76	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Xenetic Biosciences (XBIO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-2.29	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	--	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	4.00	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Xenetic Biosciences (XBIO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	-40.00	53.56	-30.01	32.82	15.61
ROE (%)	-36.75	110.09	163.18	42.98	430.03
ROA (%)	-35.06	15.64	31.68	29.32	16.19
EBIT Margin (%)	-15.64	21.13	5.73	31.04	36.28
Net Margin (%)	-75.90	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	--	0.00	0.00	0.00	0.00

Growth Ratios

	Xenetic Biosciences (XBIO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	33.30	24.67	114.85	9.23	41.15
EBIT Growth (%)	54.05	18.70	136.39	-3.99	-14.99
Net Profit Growth (%)	19.72	17.50	378.76	42.89	-25.78
EPS Growth (%)	40.60	26.84	353.27	50.42	-23.48
Book Value Growth (%)	-8.28	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Xenetic Biosciences (XBIO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-1.85	36.06	-59.76	15.79	24.99
Price / Book Value	0.67	35.44	-80.42	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	1.09	28.08	-121.54	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Xenetic Biosciences (XBIO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.00	0.27	0.00	13.50
Short term debt to equity ratio	0.00	0.00	0.05	0.00	1.46
Current Ratio	7.43	0.73	2.99	3.46	2.71
Quick Ratio	7.43	0.73	2.32	3.38	2.31
Interest Coverage	--	--	1.62	--	29.73

Operating Efficiency Ratios

	Xenetic Biosciences (XBIO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	0.00	15.88	21.25	13.74	27.40
Asset Turnover	0.46	0.89	0.44	0.83	0.65
Receivable days	--	50.42	85.52	43.48	98.04
Inventory Days	--	--	1,056.70	96.17	190.34
Payable days	--	6.26	331.01	147.97	18.62
Cash Conversion Cycle	--	--	811.21	-8.32	269.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly